10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine.
In Vitro
Concentrations of Sapacitabine required to achieve an IC 50 range from 3±0.6 μM for the colon cancer cell line HCT116 to 67±14 μM for the breast cancer cell line MDA-MB-435. Cell cycle analysis shows that 35% Sapacitabine-treated cells are arrested in late-S phase and 41% in G 2 /M phase. L1210 cells with deoxycytidine kinase (dCK) activity are sensitive to Sapacitabine, (IC 50 20±6 μM). In the docetaxel/Sapacitabine combinations, synergistic effects (CI<1) are observed when docetaxel is given before Sapacitabine in both cell lines. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
On Day 14, the Sapacitabine (5 mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 245 mm 3 and a tumour growth inhibition (TGI) of 92%, whereas the Sapacitabine (15 mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 107 mm 3 and a TGI of 112%. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal administration
Female (nu/nu) mice are injected subcutaneously with 1×10 7 MV4-11 cells resuspended in 50% Matrigel at a single site on their flanks. Once tumour volumes are 126 to 256 mm 3 (16 days post-implantation) animals are pair matched by tumour size into treatment groups (minimum of six mice per group) with a mean tumour size of ~190 mm 3 . Tumour measurements are calculated using the formula: volume (mm 3 )=width 2 (mm)×length (mm)×0.5. Sapacitabine is administered once a day orally (5 or 15 mg/kg) for 4 days , followed by a 3-day break before another 4 days of treatment; dosing starts on the same day as distribution to the treatment groups . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:nucleoside analog
| ALogP | 5.2 |
|---|
| Isomeric SMILES | CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)C#N |
|---|---|
| Alternate CAS | 151823-14-2 |
| PubChem CID | 153970 |
| MeSH Entry Terms | 2'-C-cyano-2'-deoxy-1-arabinofuranosyl-N(4)-palmitoylcytosine;CNDAC cpd;CS-682;CYC 682;CYC-682;sapacitabine |
| Molecular Weight | 490.64 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →
